# Bioventus Inc.: financial statements, quarterly

BVS · Nasdaq · CIK 1665988 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bvs.md) · [Financials](/companies/bvs/financials.md) · [Filings](/companies/bvs/filings.md) · [Insiders](/companies/bvs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bvs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [121](/filings/0001628280-24-045114.md) | [135 d](/filings/0001665988-26-000011.md) | [129](/filings/0001628280-25-022401.md) | [151](/filings/0001665988-25-000017.md) | [139](/filings/0001665988-25-000026.md) | [154 d](/filings/0001665988-26-000011.md) | [124](/filings/0001665988-26-000027.md) | [148](/filings/0001665988-26-000042.md) | [139](/filings/0001665988-25-000026.md) | [158 d](/filings/0001665988-26-000011.md) | [132](/filings/0001665988-26-000027.md) | [153](/filings/0001665988-26-000042.md) |
| Cost of revenue | $m | [41.9](/filings/0001628280-24-045114.md) | [49.1 d](/filings/0001665988-26-000011.md) | [41.1](/filings/0001628280-25-022401.md) | [47.6](/filings/0001665988-25-000017.md) | [45.4](/filings/0001665988-25-000026.md) | [51.0 d](/filings/0001665988-26-000011.md) | [40.8](/filings/0001665988-26-000027.md) | [45.6](/filings/0001665988-26-000042.md) | [44.4](/filings/0001665988-25-000026.md) | [49.1 d](/filings/0001665988-26-000011.md) | [41.3](/filings/0001665988-26-000027.md) | [47.5](/filings/0001665988-26-000042.md) |
| Gross profit | $m | [78.9](/filings/0001628280-24-045114.md) | [86.3 d](/filings/0001665988-26-000011.md) | [88.4](/filings/0001628280-25-022401.md) | [104](/filings/0001665988-25-000017.md) | [93.6](/filings/0001665988-25-000026.md) | [103 d](/filings/0001665988-26-000011.md) | [83.1](/filings/0001665988-26-000027.md) | [102](/filings/0001665988-26-000042.md) | [94.2](/filings/0001665988-25-000026.md) | [109 d](/filings/0001665988-26-000011.md) | [90.8](/filings/0001665988-26-000027.md) | [106](/filings/0001665988-26-000042.md) |
| Research and development | $m | [3.0](/filings/0001628280-24-045114.md) | [3.3 d](/filings/0001665988-26-000011.md) | [2.6](/filings/0001628280-25-022401.md) | [4.2](/filings/0001665988-25-000017.md) | [3.8](/filings/0001665988-25-000026.md) | [3.3 d](/filings/0001665988-26-000011.md) | [3.0](/filings/0001665988-26-000027.md) | [3.2](/filings/0001665988-26-000042.md) | [2.9](/filings/0001665988-25-000026.md) | [3.0 d](/filings/0001665988-26-000011.md) | [2.5](/filings/0001665988-26-000027.md) | [3.2](/filings/0001665988-26-000042.md) |
| Selling, general and administrative | $m | [69.8](/filings/0001628280-24-045114.md) | [78.4 d](/filings/0001665988-26-000011.md) | [78.8](/filings/0001628280-25-022401.md) | [96.7](/filings/0001665988-25-000017.md) | [81.5](/filings/0001665988-25-000026.md) | [86.9 d](/filings/0001665988-26-000011.md) | [73.5](/filings/0001665988-26-000027.md) | [79.1](/filings/0001665988-26-000042.md) | [78.7](/filings/0001665988-25-000026.md) | [82.8 d](/filings/0001665988-26-000011.md) | [78.3](/filings/0001665988-26-000027.md) | [82.7](/filings/0001665988-26-000042.md) |
| Operating income | $m | [2.4](/filings/0001628280-24-045114.md) | [1.2 d](/filings/0001665988-26-000011.md) | [4.9](/filings/0001628280-25-022401.md) | [(31.5)](/filings/0001665988-25-000017.md) | [3.6](/filings/0001665988-25-000026.md) | [7.7 d](/filings/0001665988-26-000011.md) | [4.9](/filings/0001665988-26-000027.md) | [18.4](/filings/0001665988-26-000042.md) | [11.3](/filings/0001665988-25-000026.md) | [19.5 d](/filings/0001665988-26-000011.md) | [8.4](/filings/0001665988-26-000027.md) | [19.1](/filings/0001665988-26-000042.md) |
| Income tax | $m | [0.6](/filings/0001628280-24-045114.md) | [(0.8) d](/filings/0001665988-26-000011.md) | [0.9](/filings/0001628280-25-022401.md) | [(7.3)](/filings/0001665988-25-000017.md) | [0.6](/filings/0001665988-25-000026.md) | [0.6 d](/filings/0001665988-26-000011.md) | [(0.1)](/filings/0001665988-26-000027.md) | [1.0](/filings/0001665988-26-000042.md) | [0.7](/filings/0001665988-25-000026.md) | [(3.2) d](/filings/0001665988-26-000011.md) | [0.6](/filings/0001665988-26-000027.md) | [(20.9)](/filings/0001665988-26-000042.md) |
| Net income | $m | [(7.3)](/filings/0001628280-24-045114.md) | [(6.1) d](/filings/0001665988-26-000011.md) | [(4.9)](/filings/0001628280-25-022401.md) | [(25.7)](/filings/0001665988-25-000017.md) | [(5.2)](/filings/0001665988-25-000026.md) | [(0.4) d](/filings/0001665988-26-000011.md) | [(2.6)](/filings/0001665988-26-000027.md) | [7.5](/filings/0001665988-26-000042.md) | [3.2](/filings/0001665988-25-000026.md) | [14.8 d](/filings/0001665988-26-000011.md) | [3.1](/filings/0001665988-26-000027.md) | [33.4](/filings/0001665988-26-000042.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001628280-24-045114.md) | not reported | [(0.08)](/filings/0001628280-25-022401.md) | [(0.40)](/filings/0001665988-25-000017.md) | [(0.08)](/filings/0001665988-25-000026.md) | not reported | [(0.04)](/filings/0001665988-26-000027.md) | [0.11](/filings/0001665988-26-000042.md) | [0.05](/filings/0001665988-25-000026.md) | not reported | [0.04](/filings/0001665988-26-000027.md) | [0.47](/filings/0001665988-26-000042.md) |
| Basic EPS | $ per share | [(0.12)](/filings/0001628280-24-045114.md) | not reported | [(0.08)](/filings/0001628280-25-022401.md) | [(0.40)](/filings/0001665988-25-000017.md) | [(0.08)](/filings/0001665988-25-000026.md) | not reported | [(0.04)](/filings/0001665988-26-000027.md) | [0.11](/filings/0001665988-26-000042.md) | [0.05](/filings/0001665988-25-000026.md) | not reported | [0.05](/filings/0001665988-26-000027.md) | [0.49](/filings/0001665988-26-000042.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.8](/filings/0001628280-23-037185.md) | [37.0](/filings/0001628280-25-011831.md) | [25.2](/filings/0001628280-24-020846.md) | [32.0](/filings/0001628280-24-034979.md) | [43.1](/filings/0001628280-24-045114.md) | [41.6](/filings/0001665988-26-000011.md) | [22.8](/filings/0001628280-25-022401.md) | [32.9](/filings/0001665988-25-000017.md) | [42.2](/filings/0001665988-25-000026.md) | [51.2](/filings/0001665988-26-000042.md) | [35.8](/filings/0001665988-26-000027.md) | [29.5](/filings/0001665988-26-000042.md) |
| Current assets | $m | [249](/filings/0001628280-23-037185.md) | [268](/filings/0001628280-25-011831.md) | [266](/filings/0001628280-24-020846.md) | [309](/filings/0001628280-24-034979.md) | [299](/filings/0001628280-24-045114.md) | [276](/filings/0001665988-26-000011.md) | [249](/filings/0001628280-25-022401.md) | [275](/filings/0001665988-25-000017.md) | [281](/filings/0001665988-25-000026.md) | [273](/filings/0001665988-26-000042.md) | [250](/filings/0001665988-26-000027.md) | [258](/filings/0001665988-26-000042.md) |
| Total assets | $m | [811](/filings/0001628280-23-037185.md) | [811](/filings/0001628280-25-011831.md) | [794](/filings/0001628280-24-020846.md) | [792](/filings/0001628280-24-034979.md) | [769](/filings/0001628280-24-045114.md) | [728](/filings/0001665988-26-000011.md) | [691](/filings/0001628280-25-022401.md) | [707](/filings/0001665988-25-000017.md) | [702](/filings/0001665988-25-000026.md) | [684](/filings/0001665988-26-000042.md) | [651](/filings/0001665988-26-000027.md) | [673](/filings/0001665988-26-000042.md) |
| Current liabilities | $m | [161](/filings/0001628280-23-037185.md) | [175](/filings/0001628280-25-011831.md) | [173](/filings/0001628280-24-020846.md) | [231](/filings/0001628280-24-034979.md) | [211](/filings/0001628280-24-045114.md) | [210](/filings/0001665988-26-000011.md) | [175](/filings/0001628280-25-022401.md) | [186](/filings/0001665988-25-000017.md) | [162](/filings/0001665988-25-000026.md) | [160](/filings/0001665988-26-000042.md) | [148](/filings/0001665988-26-000027.md) | [152](/filings/0001665988-26-000042.md) |
| Total liabilities | $m | [585](/filings/0001628280-23-037185.md) | [590](/filings/0001628280-25-011831.md) | [577](/filings/0001628280-24-020846.md) | [603](/filings/0001628280-24-034979.md) | [583](/filings/0001628280-24-045114.md) | [542](/filings/0001665988-26-000011.md) | [506](/filings/0001628280-25-022401.md) | [505](/filings/0001665988-25-000017.md) | [494](/filings/0001665988-25-000026.md) | [455](/filings/0001665988-26-000042.md) | [416](/filings/0001665988-26-000027.md) | [396](/filings/0001665988-26-000042.md) |
| Long-term debt | $m | [375](/filings/0001628280-23-037185.md) | [367](/filings/0001628280-25-011831.md) | [355](/filings/0001628280-24-020846.md) | [345](/filings/0001628280-24-034979.md) | [345](/filings/0001628280-24-045114.md) | [308](/filings/0001665988-26-000011.md) | [309](/filings/0001628280-25-022401.md) | [298](/filings/0001665988-25-000017.md) | [311](/filings/0001665988-25-000026.md) | [279](/filings/0001665988-26-000042.md) | [253](/filings/0001665988-26-000027.md) | [230](/filings/0001665988-26-000042.md) |
| Current portion of debt | $m | [19.6](/filings/0001628280-23-037185.md) | [27.8](/filings/0001628280-25-011831.md) | [35.8](/filings/0001628280-24-020846.md) | [38.6](/filings/0001628280-24-034979.md) | [38.6](/filings/0001628280-24-045114.md) | [27.3](/filings/0001665988-26-000011.md) | [37.3](/filings/0001628280-25-022401.md) | [43.4](/filings/0001665988-25-000017.md) | [11.3](/filings/0001665988-25-000026.md) | [15.0](/filings/0001665988-26-000042.md) | [18.8](/filings/0001665988-26-000027.md) | [18.8](/filings/0001665988-26-000042.md) |
| Shareholders' equity | $m | [178](/filings/0001628280-23-037185.md) | [174](/filings/0001628280-25-011831.md) | [171](/filings/0001628280-24-020846.md) | [151](/filings/0001628280-24-034979.md) | [149](/filings/0001628280-24-045114.md) | [148](/filings/0001665988-26-000011.md) | [148](/filings/0001628280-25-022401.md) | [161](/filings/0001665988-25-000017.md) | [166](/filings/0001665988-25-000026.md) | [184](/filings/0001665988-26-000042.md) | [189](/filings/0001665988-26-000027.md) | [228](/filings/0001665988-26-000042.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.3) d](/filings/0001628280-24-045114.md) | [10.4 d](/filings/0001665988-26-000011.md) | [(6.0)](/filings/0001628280-25-022401.md) | [15.2 d](/filings/0001665988-25-000017.md) | [10.3 d](/filings/0001665988-25-000026.md) | [19.3 d](/filings/0001665988-26-000011.md) | [(19.3)](/filings/0001665988-26-000027.md) | [25.9 d](/filings/0001665988-26-000042.md) | [30.1 d](/filings/0001665988-25-000026.md) | [38.0 d](/filings/0001665988-26-000011.md) | [8.9](/filings/0001665988-26-000027.md) | [19.9 d](/filings/0001665988-26-000042.md) |
| Capital expenditure | $m | [2.0 d](/filings/0001628280-24-045114.md) | [0.4 d](/filings/0001665988-26-000011.md) | [0.3](/filings/0001628280-25-022401.md) | [0.1 d](/filings/0001665988-25-000017.md) | [0.1 d](/filings/0001665988-25-000026.md) | [0.6 d](/filings/0001665988-26-000011.md) | [0.8](/filings/0001665988-26-000027.md) | [0.7 d](/filings/0001665988-26-000042.md) | [0.5 d](/filings/0001665988-25-000026.md) | [0.6 d](/filings/0001665988-26-000011.md) | [0.6](/filings/0001665988-26-000027.md) | [1.0 d](/filings/0001665988-26-000042.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [61.7](/filings/0001628280-23-037185.md) | [62.1](/filings/0001628280-24-020846.md) | [62.6](/filings/0001628280-24-034979.md) | [62.8](/filings/0001628280-24-045114.md) | [63.4](/filings/0001628280-25-022401.md) | [64.1](/filings/0001665988-25-000017.md) | [65.3](/filings/0001665988-25-000026.md) | [66.0](/filings/0001665988-26-000027.md) | [68.5](/filings/0001665988-26-000042.md) | [68.8](/filings/0001665988-25-000026.md) | [70.0](/filings/0001665988-26-000027.md) | [70.8](/filings/0001665988-26-000042.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.